30 Day Trial

Zimmer Biomet Reports 2015 Revenue

Share:

Zimmer Biomet posted 2015 revenue of US $5,998MM, growth of +28.3% vs. 2014 as reported, and 4Q15 revenue of $1,934MM, +58.1% as reported and +0.5% adjusted billing day pro forma constant currency basis.

2015 growth by segment, as reported:

  • Knees $2,276.8MM, +20.1%
  • Hips $1,537.2MM, +15.9%
  • S.E.T.* $1,215.9MM, +40.7%
  • Dental $335.7MM, +38.2%
  • Spine & CMF $404.4MM, +95.2%
  • Other $229.0MM, +65.3%

*S.E.T. includes Surgical, Sports Medicine, Foot/Ankle, Extremities and Trauma

Zimmer's overall revenue figure includes Biomet revenue from the date of acquisition, and does not account for the portion of Biomet sales prior to that.

Source: Zimmer Biomet, Inc.

 

It's worthy to note that we've tracked Biomet and Zimmer revenue throughout the years, and when we publish estimates for 2015 revenue in the next installment of THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, readers will see that revenue for the combined companies will not show a growth increase for 2015. 

This is not a surprise, given merger-related product divestitures, combining some similar product lines, ironing out dissynergies, etc. 

Company leadership has noted sequential quarterly improvement in its U.S. joint recon and S.E.T. businesses. For overall revenue, company leadership voiced an expectation of 1Q16 CC growth at +0.5% to +1%, and full-year 2016 pro forma revenue growth in a range of +1.5% to +2.5% CC.

ORTHOWORLD estimates 2015 segment sales and growth on an as-reported basis, as follows.

  • Joint Reconstruction $4,915.0MM, -5.6%
  • Trauma $501.4MM, -2.0%
  • Arthroscopy/Soft Tissue Repair $114.9MM, -1.4%
  • Spine $294.3MM, -3.1%
  • Orthobiologics $273.0MM, -5.0%